A close up of a map Description automatically generated

JAK inhibition plus TCS lead to high clearance rates in AD

Expert Name
Prof. Kristian Reich

In addition to skin clearance, baricitinib in combination with topical corticosteroid (TCS) showed to be particularly effective in pruritus reduction and improvement of sleep in adult patients with moderate-to-severe atopic dermatitis (AD) [1]. Baricitinib is a selective Janus kinase (JAK) 1 and 2 inhibitor that has previously shown to be effective in moderate-to-severe AD when given as monotherapy. The BREEEZE-AD7…

Biologics: increasingly used in paediatric dermatology

Expert Name
Prof. Marieke Seyger

Biologics and cytokine blockers are increasingly used in children and adolescents with moderate-to-severe psoriasis and atopic dermatitis (AD). Data shows that they cause less side effects than systemic conventional therapies [1]. In adults, biologics targeting specific cytokines are effective, well tolerated, and a safe alternative to conventional systemic treatments. At present, 3 biologics (i.e. etanercept, adalimumab, and ustekinumab) are approved…

A close up of a map Description automatically generated

IL-4/IL-13 blockade leads to rapid itch reduction in adolescents

Expert Name
Prof. Eric Simpson

A post-hoc analysis of the phase 3 trial LIBERTY AD ADOL showed that dupilumab entails a rapid itch reduction after only 5 days in adolescents with moderate-to-severe atopic dermatitis (AD) [1]. Itch is the moth bothersome symptom for patients with AD most and it is furthermore associated with sleep loss, reduced quality of life, and reduced productivity. “With our analysis,…

Can JAK inhibitors close the current therapeutic gap in AD?

Expert Name
Prof. Eric Simpson

Immune dysfunction and epidermal barrier dysfunction are two key factors in the atopic dermatitis (AD) pathogenesis. “In my belief, the most promising approach is not improving the barrier function, but primarily using anti-inflammatory agents,” said Prof. Eric Simpson (Oregon Health & Science University, USA) [1]. At present, there are two important therapeutic gaps: “We need a more efficacious topical therapy…

Food triggers eczema – an imperturbable belief of patients

Expert Name
Dr Peter Lio

Dr Peter Lio (Northwestern University Chicago, USA) discussed possible food triggers in eczema patients [1]. The role of food allergies is not only an important issue for patients but also for clinicians. Patients are often convinced that food is the main driver of their atopic dermatitis (AD), or parents believe it is a trigger in their children with AD. Studies…

New and emerging atopic dermatitis therapies

Expert Name
Prof. David Cohen

The therapeutic landscape of atopic dermatitis changed tremendously in the previous decade. Novel insights into the pathogenesis enabled researchers to find important targets for therapy. With regard to topical therapy, novel hyperselective phosphodiesterase-4 blockers show promising results. Increased cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity in peripheral blood leukocytes is associated with the immune and inflammatory hyperreactivity that characterises atopic…

Bermekimab – a future treatment for atopic dermatitis?

Expert Name
Dr Eric Simpson

Atopic dermatitis (AD) involves barrier defects of the epidermis as well as skin inflammation and is often characterised by a debilitating itch. The role of interleukin-1 alpha (IL-1⍺) is not yet completely understood. “It is not clear what role IL-1⍺ plays in skin, but it is already an important player in oncology,” said Prof. Eric Simpson (Oregon Health & Science…

Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD

Expert Name
E. Guttman-Yassky

The fully human, monoclonal, IL-13 blocker tralokinumab showed to be highly effective in patients with moderate-to-severe atopic dermatitis (AD) [1]. Dysregulation of cell-mediated immune response plays a key role in the pathogenesis of AD. As a result, IL-13 and other type 2 cytokines are overexpressed. The presented phase 2b trial included 204 adult patients with moderate-to-severe AD. For 12 weeks,…

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Expert Name
Prof. Peter van de Kerkhof

Prof. Peter van de Kerkhof (Radboud University Medical Center, the Netherlands) presented situations where dimethyl fumarate might be considered as a first-line treatment for psoriasis. Acitretin (synthesised retinoic acid) has a potent activity in pustular psoriasis and erythrodermic psoriasis as monotherapy. In chronic plaque psoriasis, it has a strong therapeutic activity, particularly in combination with phototherapy/UVB. Dimethyl fumarate and acitretin…

Atopic dermatitis and psoriasis: on a spectrum?

Prof. Emma Guttman-Yassky (Mount Sinai Medical School, USA) shakes down the similarities and differences between psoriasis vulgaris and chronic atopic dermatitis (AD) and concludes that they fall under the same pathomechanistic umbrella but with very distinct features [1]. For example, both psoriasis vulgaris and chronic AD are generally characterised by nearly indistinguishable histological psoriasiform dermatitis. At a mechanistic level we…